ConductScience.org, home

Comparison · NCT02239120-deaths

Dabigatran Etexilate 110 or 150 Milligram (mg) vs Acetylsalicylic Acid, Aspirin (ASA) 100 mg: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Dabigatran Etexilate 110 or 150 Milligram (mg) vs Acetylsalicylic Acid, Aspirin (ASA) 100 mg: deaths from any cause. Trial comparisons, record NCT02239120-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02239120-deaths

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.02080.0160.0269wilson
Risk in group 20.02150.01670.0277wilson
Risk difference, group 1 minus group 2-0.000742-0.008550.00705newcombe hybrid score
Risk ratio, group 1 over group 20.9660.6711.39log
Odds ratio, group 1 over group 20.9650.6661.4log
Number needed to treat, for one fewer death from any cause on Dabigatran Etexilate 110 or 150 Milligram (mg) than on Acetylsalicylic Acid, Aspirin (ASA) 100 mg1,350from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Dabigatran Etexilate 110 or 150 Milligram (mg)
Participants were orally administered one 110 mg (for participants aged ≥75 years or with a creatinine clearance (CrCl) of 30 to \<50 millilitre/ minute (mL/min)) or one 150 mg (for participants aged \<75 years and with a CrCl of ≥50 mL/minute) Dabigatran etexilate (DE) capsule twice daily.
562,695EG000
Group 2Acetylsalicylic Acid, Aspirin (ASA) 100 mgParticipants were orally administered one 100 mg Aspirin non-enteric coated tablet once daily.582,695EG001

Harm

What it counts
Total, all-cause mortality
Time frame
Adverse Events (AE) and serious AE starting between the first trial medication intake up to 6 days after the last trial medication intake, approximately 42 months. All-cause mortality reported from randomisation until full follow up period, approximately 43 months.

Source ClinicalTrials.gov

Trial

Title
Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)
NCT number
NCT02239120
Phases
PHASE3
Conditions
Stroke, Secondary Prevention
Interventions
optional ASA as comedication, placebo to ASA, placebo to optional ASA as comedication, placebo to dabigatran etexilate, ASA 100 mg, dabigatran etexilate
Lead sponsor
Boehringer Ingelheim
Results first posted
2019-09-06

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNone stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT02239120-deaths